Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Matinas BioPharma Holdings, Inc. (MTNB)

Matinas BioPharma receives NYSE American notice over $1.8 million stockholders' equity

Negative Impact 4 of 5 legal/regulatory Written later

Matinas BioPharma received an NYSE American notice on August 31, 2026, saying it fails the $2.0 million stockholders' equity standard because its equity was $1.8 million as of June 30, 2026. The company already had two other listing deficiencies, and the exchange has granted a plan period through October 2, 2027, after which delisting proceedings may start if it has not regained compliance.

Key points

  • Stockholders' equity was $1.8 million as of June 30, 2026, below the $2.0 million minimum under NYSE American Section 1003(a)(i).
  • The company is also out of compliance with Sections 1003(a)(ii) ($4.0 million) and 1003(a)(iii) ($6.0 million), as disclosed in earlier filings.
  • The NYSE American accepted the company's May 4, 2026 plan and set a plan period deadline of October 2, 2027.
  • Shares continue to trade as MTNB on the NYSE American during the plan period, with a .BC indicator attached.

The filing

CompanyMatinas BioPharma Holdings, Inc. (MTNB)
Form8-K, current report
Filed with the SECSep 4, 2026, 5:00 PM ET
Accession number0001493152-26-041577

Items reported: 3.01 Delisting / Listing Rule Notice8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.